Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

Dow Futures Push Higher After Breaking 50,000: Why OPGN, ACHR, LI, HIMS, CING Are Trending Today ↗

Topics Intellectual Property Law Enforcement

February 08, 2026

A Billion-Dollar Kickoff: Super Bowl LX Prediction Markets Hit Record $1B in Trading Volume

Topics Stocks

February 08, 2026

As the Seattle Seahawks and New England Patriots prepare to take the field for Super Bowl LX at Levi’s Stadium, the real action is happening on digital ledger boards and order books. In a historic...

Via PredictStreet

Topics Derivatives

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗

February 05, 2026

Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill ↗

February 05, 2026

HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test ↗

February 04, 2026

Why Is HIMS Stock Slipping Premarket Today? ↗

January 12, 2026

HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗

February 06, 2026

The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs.

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗

February 05, 2026

The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs.

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

Topics Fraud Law Enforcement

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Hims & Hers Takes On Novo Nordisk: What We Know Right Now ↗

February 05, 2026

Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.

Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Why Eli Lilly Stock Just Dropped ↗

February 05, 2026

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗

February 05, 2026

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

Topics Intellectual Property

February 05, 2026

From Hims & Hers

Hims & Hers is moving beyond prescriptions to preventative testing.

HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering ↗

February 04, 2026

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

February 04, 2026

From Hims & Hers

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

1 Volatile Stock for Long-Term Investors and 2 We Brush Off

February 03, 2026

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

February 02, 2026

From Hims & Hers

Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach...

Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q3 Earnings?

February 01, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks?

Topics Stocks

Will Netflix Go All-Cash for WBD? ↗

January 29, 2026

Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over

Topics Artificial Intelligence

January 29, 2026

From Hims & Hers

When you find winning stocks, stick with them.

2 Top Stocks to Double Up On Right Now ↗

January 20, 2026

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing...

Topics Artificial Intelligence

Why Hims & Hers Health (HIMS) Stock Is Down Today

January 20, 2026

Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗

Topics Artificial Intelligence

January 12, 2026

Are you looking for investment opportunities in 2026?

Topics Stocks

Stocks to Love in 2026 ↗

January 11, 2026